Next Phase Newsletter

The firm is the corporate venture arm of a senior living communities with in multiple locations and a seniors members club . The firm invests strategically in companies that can enhance their services or the elderly population quality of life in general, including in healthcare. Within healthcare, the firm is willing to invest in digital health, medical devices and diagnostic/monitoring technologies, but will not invest in therapeutics. The firm generally invests in seed to series A, and will occasionally act as a company builder, co-founding a company around a promising technology. In an initial investment, the firm will generally invest no more than $.5M, but has the ability to invest in follow-on rounds. As a strategic investor, in addition to capital, the firm can employ their facilities for pilot programs, and will occasionally do so before investing. The firm is primarily interested in Israeli companies, but will invest globally.

The firm invests in multiple sectors related to the elderly population quality of life. These technologies can include medical devices, diagnostics and digital health technologies. Examples include chronic disease management software or monitoring devices.

The firm is a strategic and active investor, and will generally take a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a venture capital investment firm founded in 2018 and is based in Germany. The firm is actively seeking medtech investment opportunities from Seed to Series B financing rounds, though the firm’s sweet spot is leading Series A investments. Initial check sizes can largely vary; the firm can invest anywhere from €1-5M, and seeks to invest €5-8M over the life of investment. With the current fund, the firm manages 5 portfolio companies, and seeks to invest in ~12 companies, for which the firm estimates 2/3 will be Europe/Israel-based companies, and 1/3 will be USA-based companies. Currently, the firm is not evaluating opportunities outside of USA, Europe, and Israel.

The firm is focused on investing in innovative medical devices that address cardiovascular or neurovascular disease. The firm does not invest in other sectors such as therapeutics, diagnostics, or digital health. Within medical devices, the firm is open to both pre-clinical (prototype) and clinical technologies. The firm has primarily evaluated PMA devices but is open to 510k regulatory pathways. The firm may consider other types of devices on a highly selective basis, but even such opportunities must have some connection or relevance to cardiovascular disease.

The firm prefers to lead investment rounds and seek board representation, though the firm can also co-invest alongside syndicates. Through the firm’s relationship with a proprietary commercialization and distribution platform, the firm is uniquely positioned to create value for their portfolio companies in the European market. Through this sister company relationship, the firm has access to a wide network including over 200 European hospitals, clinical sites, physicians, KOLs, etc. and can provide strategic advice on market strategy (EU clinical trials, regulatory process, reimbursement).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm, headquartered in Mountain View, CA, is a multinational healthcare technology company which develops, manufactures, and sells solutions to support the vision of a fully autonomous pharmacy. The company is focused on transforming the pharmacy care delivery model and executing on the vision of the autonomous pharmacy by delivering automation, intelligence, and advanced services, powered by a single, cloud-based platform. The firm offers medication management automation solutions and adherence tools which empower healthcare systems and pharmacies to focus on clinical care rather than administrative tasks.

The firm is looking for global strategic partnerships with companies from their formation to commercialization. The company considers a variety of engagement models including acquisitions, collaborations and strategic investments when partnering with companies aligned with the company’s core business and new areas of strategic interest.
The firm is looking for global strategic partnerships with companies from their formation to commercialization. The company considers a variety of engagement models including acquisitions, research collaborations and strategic investments when partnering with companies aligned with the firm’s core business and new areas of strategic interest.

The firm is looking for strategic partnerships with early-stage companies in the medical device and digital health sectors. The company is open to subsector and indication as it relates to the company’s core business interest. The firm is open to pre-prototype companies and will consider class 1 and 2 medical device technologies.

The firm is open to all types of management teams with technologies relating to their focus and who have an interest in a strategic partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Founded in 1960 the company is an international corporation that manufactures research tools and scientific instrumentation. Within the life sciences, the firm’s main focus is on instrumentation for research, including spatial biology, -omics platforms, and single cell analysis. The company has multiple partnership models including: investing, co-development, and acquisition. The firm is willing to partner globally, and prefers companies that have a pilot proof-of-concept with a potential client and a plan for early revenue before partnering with them.

Within instrumentation, the company partners with companies that are a strategic fit for the firm. The areas of interest include: spatial biology, microfluidic devices, -omics platforms, single cell analysis, and analytics. The firm’s main focus is on tools that are primarily for research use only, but will consider clinical diagnostics as well, especially when they are platform technologies with applications for both research and the clinic.

The company has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The family office has offices in Belgium and Luxembourg. The firm makes equity investments in life science companies, typically at the Series A stage or later; the firm allocates a total of EUR 3-15 million over the life of an investment. The majority of the firm’s investments are in Europe (~75%) and the rest are in the US.

In the life science sector, the firm invests in medical applications (therapeutics, diagnostics, and medical devices), digital health, life science services and tools, and agtech / food tech. For therapeutics companies, the firm only invests in companies with assets that have obtained data from in-human clinical trials (at minimum, human safety data is required). For medtech or diagnostic companies, the product must be no more than 1 year from commercialization. For digital health companies, the firm prefers to see companies that have market traction, with 2-3M EUR in revenue. In life science tools, the firm is particularly interested in companies with technologies in the -omics space, drug design platforms, or relating to data. The firm invests broadly in the life science field, but has a specific interest in technologies at the intersection between the healthcare and food industries, including nutraceuticals and the microbiome.

The firm is a hands-on investor that prefers to take a board seat and work closely with management. The firm prefers to invest as part of a strong syndicate that includes experienced investors with whom the firm has pre-existing connections.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

By Caitlin Dolegowski, Marketing Specialist, LSN

Digital RESI JPM, January 11-13 is Life Science Nation (LSN)’s first partnering event of 2022 and features a lineup of must-see panels. These panels are organized with consideration of fundraising, life science entrepreneurs and insights they can learn from expert panelists, featuring unique conversations on how to build relationships and manage expectations in the early-stage fundraising arena. Those attending Digital RESI JPM will have access to the live panels and, additionally, each panel will be recorded and a link to the recordings will be available on our platform for conference attendees to access at their convenience.

Panels at Digital RESI JPM:

Bodil (Bo) Arlander Lead Venture Partner, Portfolia Active Aging & Longevity Fund Portfolia	Joshua Barney Member Barrington Angels	Mel Barsky Director, BD CABHI
Yael Benvenisti CEO Mediterranean Tower Ventures	Jean Anne Booth Founder & CEO UnaliWear Inc.	David Bravo CEO Pannex Therapeutics
Christine Brocato System VP, Strategic Innovation CommonSpirit Health	Patrick Burgermeister Partner KIZOO Technology Ventures	Anke Cassing Investment Manager High-Tech Gründerfonds
Tracy Chadwell Founding Partner 1843 Capital LLC	Sam Cooper CEO Phenomic AI	Marina Cortes Venture Partner Hike Ventures LLC
Leslie Cousens Senior Director, Search & Evaluation Respiratory & Immunology AstraZeneca	Ruchi Dana Board Member Dana Group	Jun Deng Investment Partner Joyance Partners
Dominic Endicott Founding Partner 4Gen Ventures	Erin Denny Director in Business Development Amgen	Stacy Feld Senior Director, Consumer Scientific Innovation Johnson & Johnson Innovation
David Gordon Head of Investments Longliv Ventures	Richard Hanbury CEO Sana Health	Dan Hermann Managing Partner Ziegler LinkAge
Gerard Honig Director, Research Innovation Crohn’s and Colitis Foundation	Jochen Hurlebaus Head of Digital Health Innovation Roche Diagnostics	Shrenik Jain Founder & CEO Marigold Health
Rick Jones Partner BioAdvance	Ekkehard Kauffmann Global BD, M&A Roche Diagnostics	Masashi Kiyomine Partner Kicker Ventures
Stephany Lapierre Founder & CEO TealBook	Keagan Lenihan Vice President, Operations Altoida Inc	Abby Levy Managing Partner Primetime Partners
Tim Luker Senior Director, Emerging Technology & Innovation, Corporate BD Eli Lilly & Co	Fiona MacLaughlin Director Johnson & Johnson Innovation (JLABS)	Henry Mahncke CEO Posit Science
Brian Malkin Partner McDermott Will & Emery	Mark McDade Partner, Boston Qiming Venture Partners	Tom Miller Managing Partner GreyBird Ventures
Brad Murray Senior Associate Xontogeny	Heather Petty Senior Manager, Program Development Xontogeny	Rohit Pratap Singh Vice President, Investments Xeraya Capital
Marc Rippen CEO Alertgy	Roberto Rosas Director Health Innovation Capital	Kerry Rupp General Partner True Wealth Ventures
Beth Sanders Founder & CEO LifeBio	Mark Scher CEO Spiro100	Peter Schlecht CEO & Founder Braingrade
Anu Shukla Co-Founder & Executive Chair Botco.ai	Dor Skuler Co-Founder Intuition Robotics	Yaniv Sneor Founding Member Mid Atlantic Bio Angels
Michelle Snyder Investment Partner McKesson Ventures	John Steuart Managing Director Steuart Ventures	Frances Taheri Global Ventures Digital Health Lead Accenture Ventures
Lauren Tyra Analyst Green Park & Golf Ventures	David Uffer Senior Partner Alira Health Ventures	Hope Walls Investment Analyst Nationwide Ventures
Tad Weems Managing Director Agilent Technologies	Sam Yang Managing Director and Co-Founder Xandar Kardian	Renee Yao Global Healthcare AI Startups BD Lead NVIDIA Corporation
Max Zamkow Partner Third Act Ventures	Lu Zhang Managing Partner Fusion Fund	Mishael Zohar Associate OrbiMed Advisors LLC

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

Startups can save precious time and resources by seeking investments at Redefining Early Stage Investments (RESI), but service providers like Contract Research Organizations (CROs) are also there to help them achieve their goals better, faster, and cheaper. Designed to simplify entry into drug markets and reduce product development cost for life science companies, CROs support the biotechnology and medical device industries in the form of research services outsourced on a contract basis. Preexisting relationships with CROs and other RESI service providers help startups hit the ground running with their new capital. There are now more than 1,000 CROs, with some serving the global market, and many using RESI to promote their model and services.

Examples:

• Wuxi Apptech (Former RESI Title Sponsor)
• Viva Biotech (Former RESI Gold Sponsor)
• Avance Clinical (Former Exhibitor on RESI Service Provider Showcase)

In addition to the R&D outsourcing model, some CRO companies also have their own incubator or corporate venture capital funds, to support early-stage clients with equity investments or “Service for Equity”, which is designed to be a win-win model. Many fundraising executives are surprised to learn such options exist; some have never even considered an overseas CRO partner. With their biggest expenditure being covered, they can then focus on finding co-investors for a smaller round.

If you want to showcase your CRO brand to more startups in Therapeutics, MedTech and Diagnostics, you should not miss out Digital RESI in 2022. Check out the sponsorship brochure as below for the RESI 2022 schedule and sponsorship options.

Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International	East Coast (USA) & China	Midwest (USA) & Canada	West Coast  (USA)
Greg Mannix Vice President International Business Development Book a Meeting Email Me	Candice He VP, Business Development & Global Investment Strategist Book a Meeting Email Me	Antoinette Lowre Manager of Business Development Book a Meeting Email Me	Alexander Vassallo Manager of Business Development Book a Meeting Email Me